WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen, Inc. (NASDAQ: IMGN), a biotechnology company that develops novel anticancer therapeutics using its antibody-drug conjugate (ADC) technology, today announced the presentation of favorable clinical findings with SAR3419 (coltuximab ravtansine) from the STARLYTE Phase II trial in diffuse large B-cell lymphoma (DLBCL). SAR3419 is a CD19-targeting ADC developed by ImmunoGen and licensed to Sanofi as part of a broader collaboration between the companies. The study results were reported in an oral abstract session at the American Society of Clinical Oncology (ASCO) 50th Annual Meeting being held in Chicago, IL; they were also selected for Best of ASCO (abstract #8506).
Help employers find you! Check out all the jobs and post your resume.
